Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication

ConditionHelicobacter Pylori Eradication

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorKaohsiung Medical University

About this trial

1. Compare the efficacies and safety of 14-day bismuth-amoxicillin-vonoprazan tiple therapy, 14-day vonoprazan dual therapy and 14-day rabeprazole triple therapy in the first-line treatment of H. pylori infection. 2. To investigate the impacts of antibiotic resistance of H. pylori as well as CYP3A4, CYP2C19 and IL-1B -511 genotypes of host on the eradication efficacies of anti-H. pylori treatments.

Eligibility criteria

Qualifiers

None

Disqualifiers

Those who have ever received Helicobacter pylori sterilization treatment.

Those who are allergic to the drugs used in this research.

Those who have had stomach surgery.

Those with severe liver cirrhosis or uremia or malignant tumors.

Trial design

Treatments tested in this trial

vonoprazan, amoxicillin, tripotassium dicitrate bismuthate
vonoprazan, amoxicillin
rabeprazole, amoxicillin, clarithromycin

Treatment groups

390 Participants

are divided into 3 treatment groups

Sponsors and collaborators

Kaohsiung Medical University

Lead sponsor

Source ClinicalTrials.gov